Date: 2014-09-04
Type of information: Financing round
Company: MyCartis (Belgium)
Investors: RMM, Valiance (UK), Biover II (Belgium)
Amount: € 15 million
Funding type: financing round
Planned used: * On September 4, 2014– Biocartis announced that it has combined its Swiss Evalution business unit with Belgian-based Pronota NV to jointly form MyCartis. MyCartis also completed an € 15 million equity round.
Biocartis’ Evalution platform, previously known as DMAT, is designed for rapid and cost-effective detection of a broad range of protein and nucleic acid biomarkers, making the system valuable for many clinical and pharmaceutical applications. Pronota has discovered and validated biomarker panels for a range of diseases. As such this content is an ideal match for Biocartis’ Evalution platform. MyCartis will continue the development of biomarker panels from the current Pronota laboratories (Technology Park, Ghent), to complement the current activities in Switzerland (Parc Scientifique - EPFL, Ecublens).
Others: * On September 4, 2014, Biocartis announced that it has combined its Swiss Evalution business unit with Belgian-based Pronota NV to jointly form MyCartis. In order to execute and roll out MyCartis’ future ambitions, MyCartis has completed a financing round of € 15 million. The capital is subscribed by RMM (Rudi Mariën), Valiance and Biover II (Annie Vereecken). Paul Ladestein is appointed as MyCartis’ Chief Executive Officer. Paul joined Biocartis in 2013 as Evalution business unit manager.
Therapeutic area: Diagnostic
